PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.

Szczegóły
Abstrakt

Tytuł:: PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133.
Autorzy:: Matsushita M; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Japan.
Mori Y; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Japan.; Laboratory of Oncogenomics, Chiba Cancer Center Research Institute, Japan.
Uchiumi K; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Japan.
Ogata T; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Japan.
Nakamura M; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Japan.
Yoda H; Laboratory of Cancer Genetics, Chiba Cancer Center Research Institute, Japan.
Soda H; Department of Esophago-Gastrointestinal Surgery, Chiba Cancer Center Hospital, Japan.
Takiguchi N; Department of Esophago-Gastrointestinal Surgery, Chiba Cancer Center Hospital, Japan.
Nabeya Y; Department of Esophago-Gastrointestinal Surgery, Chiba Cancer Center Hospital, Japan.
Shimozato O; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Japan.; Laboratory of Oncogenomics, Chiba Cancer Center Research Institute, Japan.
Ozaki T; Laboratory of DNA Damage Signaling, Chiba Cancer Center Research Institute, Japan.; Laboratory of Oncogenomics, Chiba Cancer Center Research Institute, Japan.
Źródło:: FEBS open bio [FEBS Open Bio] 2019 May; Vol. 9 (5), pp. 935-946. Date of Electronic Publication: 2019 Apr 18.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: Jan. 2016- : West Sussex : John Wiley & Sons Ltd.
Original Publication: Amsterdam : Elsevier, 2011-
MeSH Terms:: AC133 Antigen/*genetics
Antineoplastic Agents/*pharmacology
Carcinogenesis/*genetics
Cell Proliferation/*genetics
Oxaliplatin/*pharmacology
Receptor-Like Protein Tyrosine Phosphatases, Class 2/*genetics
AC133 Antigen/metabolism ; Carcinogenesis/drug effects ; Cell Line, Tumor ; Disease Progression ; Drug Resistance ; HEK293 Cells ; HT29 Cells ; Humans ; Phosphorylation ; Receptor-Like Protein Tyrosine Phosphatases, Class 2/metabolism ; Signal Transduction
References:: Nat Rev Cancer. 2006 Apr;6(4):307-20. (PMID: 16557282)
Nat Rev Cancer. 2005 Apr;5(4):275-84. (PMID: 15803154)
J Biol Chem. 2006 Sep 15;281(37):27389-97. (PMID: 16849327)
Nature. 2007 Jan 4;445(7123):111-5. (PMID: 17122771)
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29. (PMID: 25559415)
Blood. 1997 Dec 15;90(12):5002-12. (PMID: 9389720)
Int J Oncol. 2013 Nov;43(5):1560-8. (PMID: 24002526)
Am J Pathol. 2005 Feb;166(2):545-55. (PMID: 15681837)
J Cancer Res Clin Oncol. 2013 Jul;139(7):1129-39. (PMID: 23552869)
Cell Stem Cell. 2007 Oct 11;1(4):389-402. (PMID: 18371377)
Nature. 2006 Dec 7;444(7120):756-60. (PMID: 17051156)
Mol Cell Biol. 1993 May;13(5):2942-51. (PMID: 8474452)
Cell. 1996 Nov 15;87(4):619-28. (PMID: 8929531)
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5. (PMID: 11121071)
Nat Rev Clin Oncol. 2015 Oct;12(10):607-19. (PMID: 26215044)
PLoS One. 2013 May 16;8(5):e62852. (PMID: 23696788)
Oncogene. 2011 Jan 6;30(1):97-105. (PMID: 20818439)
Cell. 1997 Oct 17;91(2):231-41. (PMID: 9346240)
Nature. 2009 Jan 29;457(7229):603-7. (PMID: 19092805)
Cell Stem Cell. 2011 Jan 7;8(1):59-71. (PMID: 21211782)
Mol Cell Biol. 1999 Aug;19(8):5800-10. (PMID: 10409766)
Mol Cell Biol. 2005 Jun;25(11):4703-15. (PMID: 15899872)
Eur J Cancer. 2010 Feb;46(3):642-9. (PMID: 20005089)
Blood. 2008 Dec 15;112(13):4793-807. (PMID: 19064739)
Leukemia. 2014 Apr;28(4):787-93. (PMID: 24045499)
Blood. 1997 Dec 15;90(12):5013-21. (PMID: 9389721)
Lancet. 2010 Mar 20;375(9719):1030-47. (PMID: 20304247)
Trends Cell Biol. 2005 Sep;15(9):494-501. (PMID: 16084092)
Cancer Res. 2013 Dec 1;73(23):7090-100. (PMID: 24101153)
Cell. 2016 Aug 25;166(5):1132-1146.e7. (PMID: 27565343)
Mol Biol Cell. 2002 Jul;13(7):2276-88. (PMID: 12134068)
Biochemistry. 2009 May 12;48(18):3998-4007. (PMID: 19296573)
J Biol Chem. 2005 Dec 30;280(52):42694-700. (PMID: 16263724)
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32. (PMID: 18765800)
Free Radic Res. 2010 May;44(5):479-96. (PMID: 20370557)
Genes Chromosomes Cancer. 2008 Feb;47(2):159-64. (PMID: 18008368)
Nature. 2003 Jun 12;423(6941):769-73. (PMID: 12802338)
J Pathol. 2009 Dec;219(4):427-34. (PMID: 19621338)
Oncogene. 2015 Apr 9;34(15):1949-60. (PMID: 24882578)
J Biol Chem. 1999 Dec 3;274(49):34859-67. (PMID: 10574959)
Mol Biol Cell. 2010 Jan 1;21(1):29-35. (PMID: 19864455)
Nature. 2001 Nov 1;414(6859):105-11. (PMID: 11689955)
Adv Drug Deliv Rev. 2014 Apr;69-70:29-41. (PMID: 24636868)
Biomolecules. 2015 Oct 23;5(4):2854-76. (PMID: 26512706)
Cancer Sci. 2008 Aug;99(8):1578-83. (PMID: 18754869)
Am J Pathol. 2001 Jun;158(6):1903-11. (PMID: 11395364)
Mol Cell Biol. 2006 May;26(10):3917-34. (PMID: 16648485)
Oncogene. 2008 Mar 13;27(12):1749-58. (PMID: 17891174)
J Korean Surg Soc. 2011 Oct;81(4):263-70. (PMID: 22111082)
Nat Methods. 2012 Jul;9(7):671-5. (PMID: 22930834)
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3788-93. (PMID: 15731348)
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6829-34. (PMID: 23569237)
Science. 2009 Mar 27;323(5922):1747-50. (PMID: 19251594)
Contributed Indexing:: Keywords: PTPRK; CD133; colon carcinoma; drug resistance; protein tyrosine phosphatase
Substance Nomenclature:: 0 (AC133 Antigen)
0 (Antineoplastic Agents)
0 (PROM1 protein, human)
04ZR38536J (Oxaliplatin)
EC 3.1.3.48 (PTPRK protein, human)
EC 3.1.3.48 (Receptor-Like Protein Tyrosine Phosphatases, Class 2)
Entry Date(s):: Date Created: 20190405 Date Completed: 20191112 Latest Revision: 20200309
Update Code:: 20240104
PubMed Central ID:: PMC6487712
DOI:: 10.1002/2211-5463.12636
PMID:: 30947381
: Czasopismo naukowe

Full Text Finder

Receptor-type protein tyrosine phosphatase κ (PTPRK) is considered to be a candidate tumor suppressor. PTPRK dephosphorylates CD133, which is a stem cell marker; phosphorylated CD133 accelerates xenograft tumor growth of colon cancer cells through the activation of AKT, but the functional significance of this has remained elusive. In this study, we have demonstrated that knockdown of PTPRK potentiates the pro-oncogenic CD133-AKT pathway in colon cancer cells. Intriguingly, depletion of PTPRK significantly reduced sensitivity to the anti-cancer drug oxaliplatin and was accompanied by up-regulation of phosphorylation of Bad, a downstream target of AKT. Together, our present observations strongly suggest that the CD133-PTPRK axis plays a pivotal role in the regulation of colon cancer progression as well as drug resistance.
(© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.)

Informacja